The Chemours Company
Stock Forecast, Prediction & Price Target
The Chemours Company (CC) stock Price Target by analysts
$30
Potential upside: 95.05%
The Chemours Company price prediction
What is The Chemours Company stock analysts` prediction?
The Chemours Company stock forecast: Based on 2 Wall Street analysts` predicted price targets for The Chemours Company in the last 3 months, the avarage price target is $30, with a high forecast of $NaN. The average price target represents a 95.05% change from the last price of $15.38.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
The Chemours Company stock Price Target by analysts
Full breakdown of analysts given The Chemours Company price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Arun Viswanathan RBC Capital | 33.33% 1/3 | 12 months ago | $28 82.05% upside | $19.78 | TheFly | Previous targets (2) |
John McNulty BMO Capital | 0% 0/3 | 12 months ago | $32 108.06% upside | $19.57 | TheFly | Previous targets (2) |
John McNulty BMO Capital | 0% 0/3 | about 1 year ago | $30 95.05% upside | $18.77 | StreetInsider | Previous targets (2) |
John Roberts Mizuho Securities | 0% 0/1 | over 1 year ago | $25 62.54% upside | $23.9 | TheFly | Previous targets (0) |
Rich Hilliker UBS | 0% 0/1 | over 1 year ago | $31 101.56% upside | $26.65 | StreetInsider | Previous targets (0) |
John McNulty BMO Capital | 0% 0/3 | over 1 year ago | $34 121.06% upside | $27.05 | StreetInsider | Previous targets (2) |
Emily Nassedd Mitsch CFRA | 100% 1/1 | over 1 year ago | $18 17.03% upside | $28.74 | StreetInsider | Previous targets (0) |
Joshua Spector UBS | 100% 1/1 | over 1 year ago | $28 82.05% upside | $28.74 | TheFly | Previous targets (0) |
Linda Bolton Weiser D.A. Davidson | 100% 1/1 | over 1 year ago | $24 56.04% upside | $26.84 | StreetInsider | Previous targets (0) |
Arun Viswanathan RBC Capital | 33.33% 1/3 | almost 2 years ago | $40 160.07% upside | $29.53 | Benzinga | Previous targets (2) |
Vincent Andrews Morgan Stanley | 50% 1/2 | almost 2 years ago | $33 114.56% upside | $23.58 | Benzinga | Previous targets (1) |
Arun Viswanathan RBC Capital | 33.33% 1/3 | over 2 years ago | $33 114.56% upside | $32.55 | TheFly | Previous targets (2) |
Unknown RBC Capital | N/A | over 3 years ago | $48 212.09% upside | $39.59 | Benzinga | N/A |
Matthew DeYoe Bank of America Securities | 100% 1/1 | over 4 years ago | $42 173.08% upside | $32.59 | Benzinga | Previous targets (0) |
Vincent Andrews Morgan Stanley | 50% 1/2 | over 4 years ago | $35 127.56% upside | $33.08 | StreetInsider | Previous targets (1) |
David Coleman Argus Research | 100% 1/1 | over 4 years ago | $40 160.07% upside | $33.58 | TheFly | Previous targets (0) |
The Chemours Company Financial Estimates
The Chemours Company Revenue Estimates
The Chemours Company EBITDA Estimates
The Chemours Company Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $6.34B N/A | $6.79B 7.07% | $6.02B -11.28% | Avg: $6.18B Low: $6.04B High: $6.29B avg. 2.54% | Avg: $6.38B Low: $6.16B High: $6.55B avg. 3.35% | ||
Net Income
% change YoY
| $608M N/A | $578M -4.93% | $-238M -141.17% | Avg: $531M Low: $493.76M High: $534.01M avg. 323.10% | Avg: $787M Low: $731.39M High: $791.01M avg. 48.21% | ||
EBITDA
% change YoY
| $1.20B N/A | $1.20B -0.08% | $197M -83.63% | Avg: $812.97M Low: $795.53M High: $827.72M avg. 312.67% | Avg: $840.27M Low: $811.55M High: $861.90M avg. 3.35% | ||
EPS
% change YoY
| $3.69 N/A | $3.72 0.81% | -$1.6 -143.01% | Avg: $3.47 Low: $3.32 High: $3.59 avg. 316.87% | Avg: $5.14 Low: $4.91 High: $5.31 avg. 48.12% | ||
Operating Expenses
% change YoY
| $699M N/A | $828M 18.45% | $1.39B 68.84% | Avg: $762.75M Low: $746.39M High: $776.60M avg. -45.43% | Avg: $788.37M Low: $761.43M High: $808.67M avg. 3.35% | ||
FAQ
What is The Chemours Company stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 185.66% in 2025-2026.
We have gathered data from 5 analysts. Their low estimate is 493.76M, average is 531M and high is 534.01M.
What is The Chemours Company stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2.95% in 2025-2026.
We have gathered data from 6 analysts. Their low revenue estimate is $6.04B, average is $6.18B and high is $6.29B.
What is The Chemours Company stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 182.50% in 2025-2026.
We have gathered data from 5 analysts. Their low earnings per share estimate is $3.32, average is $3.47 and high is $3.58.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering The Chemours Company stock. The most successful analyst is Arun Viswanathan whose win rate is 33.33%. He has correctly predicted 1/3 price targets.